Results from two Phase 3 randomized trials, UNCOVER-2 and UNCOVER-3, evaluating ixekizumab for moderate-to-severe psoriasis were published on 2015-01-01. These pivotal studies compared ixekizumab with etanercept or placebo in the treatment of this condition.
Background
Ixekizumab (Taltz) is a drug investigated for the treatment of moderate-to-severe psoriasis. The publication of these Phase 3 trial results represents a significant milestone in the clinical development of ixekizumab, providing comprehensive data on its efficacy and safety profile in comparison to established treatments and placebo.
Trial design
The published results are derived from two Phase 3 randomized trials, specifically named UNCOVER-2 and UNCOVER-3. These studies enrolled participants diagnosed with moderate-to-severe psoriasis. The trials were designed to compare the effects of ixekizumab against two comparator arms: etanercept, an active comparator, and placebo.
What this means
The publication of these Phase 3 trial results for ixekizumab marks a crucial step in its potential role for treating moderate-to-severe psoriasis. While specific numerical outcomes are not detailed in the provided data, the pivotal nature of these trials indicates they offer substantial evidence regarding ixekizumab's comparative efficacy and safety. Clinicians and researchers can now review the full findings to understand how ixekizumab performs relative to etanercept and placebo, informing treatment decisions and future research directions for patients with this chronic skin condition.
Source
The information regarding the publication of these trial results was obtained from PubMed. The article, titled 'Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials', was published on 2015-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.